Interventions for mycosis fungoides

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 9, 2012, Pages

  Weberschock, Tobias ^a,b   Strametz, Reinhard ^a,b   Lorenz, Maria ^c   Röllig, Christoph ^d   Bunch, Charles ^e   Bauer, Andrea ^d   Schmitt, Jochen ^c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; CHLORMETHINE; DENILEUKIN DIFTITOX; ETRETIN; HYPERICIN; IMIQUIMOD; METHOTREXATE; PELDESINE; PSORALEN;

DISEASE FREE INTERVAL; HUMAN; INCIDENCE; INTERNAL VALIDITY; MYCOSIS FUNGOIDES; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; ULTRAVIOLET A RADIATION;

EID: 84891834788     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008946.pub2     Document Type: Review

References (116)

1. Child FJ, Mitchell TJ, Whittaker SJ, Scarisbrick JJ, Seed PT, Russel-Jones R. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical & Experimental Dermatology 2004;29(3):231-6. [PUBMED: 15115499].
2. Child FJ, Mitchell TJ, Whittaker SJ, Watkins P, Seed P, Russell-Jones R. A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology 2001;145(Suppl 59):16.
3. Chong A, Loo WJ, Banney L, Grant JW, Norris PG. Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment 2004;15(2):118-9. [PUBMED: 15204164].
4. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al.Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology 2001;137(5):581-93. [PUBMED: 11346336].
5. Prince HM, McCormack C, Ryan G, Baker C, Rotstein H, Davison J, et al.Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology 2001;42(2):91-7. [PUBMED: 11309029].
6. Duvic M, Olsen EA, Omura GA, Maize JC, Vonderheid EC, et al.A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2001;44(6):940-7. [PUBMED: 11369904].
7. Guitart J, Tucker R, Stevens V. Low Dose Bexarotene (Targretin®) Capsules and Phototherapy for Early Stage Cutaneous T-Cell Lymphoma. [Abstract 199]. The 63rd Annual Meeting of the Society for Investigative Dermatology, 15-18 May, Los Angeles, USA. Journal of Investigative Dermatology 2002;119(1):241.
8. NCT00030589. A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (accessed 26 October 2011).
9. Kaye F, Eddy J, Ihde DC, Steinberg S, Fischmann AB, Glatstein E, et al.Conservative vs. aggressive therapy in mycosis fungoides [Abstract 1002]. Proceedings of the American Society of Clinical Oncology 1989;8:257.
10. Kaye F, Ihde D, Fischmann A, Glatstein E, Minna J, Schechter G, et al.A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF) [Abstract 765]. Proceedings of the American Society of Clinical Oncology 1986;5:195.
11. Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al.A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine 1989;321(26):1784-90. [PUBMED: 2594037].
12. Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, et al.Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma 2002;2(4):222-8. [PUBMED: 11970761].
13. Kuzel T, Olsen E, Martin A, Kim Y, Duvic M, Frankel A, et al.Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood 1997;90(10 Suppl 1 (Pt 1)):586a.
14. NTC00050999. Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients. clinicaltrials.gov/ct2/show/NCT00050999 (accessed 26 October 2011).
15. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al.Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology 2001;19(2):376-88. [PUBMED: 11208829].
16. Olsen E, Duvic M, Martin A. Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL) [Abstract 1234]. Journal of Investigative Dermatology 1998;110(4):678.
17. Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology 2010;63(6):984-90. [PUBMED: 20889234].
18. Otte HG, Kuhl S, Stadler R, Luger T, Henz B, Sterry W. Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt 1997;48(Suppl):S97.
19. Otte HG, Stadier R, Luger T, Henz B, Sterry W. Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL) [Poster P232]. Annals of Oncology 1996;7(Suppl 3):66.
20. Stadler R, Otte HG, Luger T, Henz BM, Kuhl P, Zwingers T, et al.Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92(10):3578-81. [PUBMED: 9808550].
21. Bohmeyer J, Otte HG, Stadler R, Luger T, Sterry W. Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results [Abstract P-447]. Journal of the European Academy of Dermatology & Venereology 1999;12(Suppl 2):S268.
22. Bohmeyer J, Stadler R, Luger T, Sterry W. Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten 2001;76(Suppl 1):S55.
23. Kremer A, Bohmeyer J, Stadler R, Luger T, Sterry W. Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft 2003;1(Suppl 1):S99.
24. Otte HG, Stadler R. combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten 1993;162(Suppl):P2.03.08.
25. Otte HG, Stadler R, Luger T, Sterry W. Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt 1999;50(Suppl 1):S2.
26. Stadler M, Kremer A, Luger T, Sterry W. Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology 2006;24(18S Pt 1):432.
27. Thestrup-Pedersen K, Grunnet E, Zachariae H. Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica 1982;62(1):47-53. [PUBMED: 6175137].
28. Vonderheid EC, Thompson R, Smiles KA, Lattanand A. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology 1987;123(6):757-63. [3579357].
29. Wolff JM, Zitelli JA, Rabin BS, Smiles KA, Abell E. Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology 1985;13(4):604-12. [PUBMED: 2934438].
30. Wozniak MB, Tracey L, Ortiz-Romero PL, Montes S, Alvarez M, Fraga J, et al.Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology 2008;160(1):92-102. [PUBMED: 18945306].
31. Argyropoulos CL, Lamberg SI, Clendenning WE, Fischmann AB, Jegasothy B, Zackheim H, et al.Preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of mycosis fungoides. Cancer Treatment Reports 1979;63(4):619-21.
32. Breneman DL, Nartker AL, Ballman EA, Pruemer JM, Blumsack RF, Davis M, et al.Topical mechlorethamine in the treatment of mycosis fungoides. Uniformity of application and potential for environmental contamination. Journal of the American Academy of Dermatology 1991;25(6 Pt 1):1059-64.
33. Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM, et al.Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Journal of Clinical Oncology 1994;12(4):769-78.
34. Currie VE, Kempin SJ, Young CW. Phase I trial of metoprine in patients with advanced cancer. Cancer Treatment Reports 1980;64(8-9):951-6.
35. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, et al.Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. British Journal of Haematology 2007;136(3):439-47. [PUBMED: 17233846].
36. Doan CA, Wiseman BK, Bouroncle BA. Clinical evaluation of CB 1348 in leukemias and lymphomas. Annals of the New York Academy of Sciences 1958;68(3):979-95.
37. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, et al.Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116(19):4541-8.
38. Fawzi M, El Mofty M, Ramadan S, Hegazy R, Sayed S. Broadband UVA versus PUVA in the treatment of early stage mycosis fungoides: A comparative study. [Abstract P99]. 6th Congress of the European Association of Dermatologic Oncology Athens Greece. 16-19 June 2010. Melanoma Research 2010;20:e85.
39. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, et al.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993;328(14):1002-6.
40. JapicCTI-050041. Post-marketing clinical study of Ogamma 100 in patients with mycosis fungoides. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-050041 (accessed 27 October 2011).
41. Kaung DT, Wittington RM, Spencer H, Patno ME. Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of malignant lymphomas. Cancer 1969;23(6):1280-3.
42. Kujawska A, Abrou A, Fivenson DP, Lim HW. PUVA vs. PUVA and interferon alpha for treatment of mycosis fungoides. [Abstract 1185]. International Investigative Dermatology. The 4th Joint Meeting of the ESDR, Japanese SID & SID, 30th April-4thMay 2003, Florida, USA. Journal of Investigative Dermatology 2003;121(1).
43. Kuzel T. Correlates of capillary leak syndrome (CLS) in patients with cutaneous T-cell lymphoma (CTCL) during treatment with denileukin diftitox (DD) in a placebo (PBO)-controlled phase III trial. [Abstract e18509]. 4-8 June 2010 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. Journal of Clinical Oncology 2010;28(15 Suppl May).
44. Lansigan F, Foss FM. Rate of infection and immunosuppression in two phase III studies of denileukin diftitox (DD) in cutaneous T-cell lymphoma (CTCL). [Abstract e18515]. 4-8 June 2010 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. Journal of Clinical Oncology 2010;28(15 Suppl May).
45. NCT00054171. Phase I Randomized Pilot Study of Photodynamic Therapy Using Aminolevulinic Acid in Patients With Cutaneous T-Cell or B-Cell Lymphoma or Early Chronic Lymphocytic Leukemia With Cutaneous Infiltrates. clinicaltrials.gov/ct/show/NCT00054171 (accessed 27 October 2011).
46. Neering H, Kroon HV, van der Roeleveld CG. Treatment of localized skin lesions with betamethasone 17-valerate and triamcinolone acetonide in alcoholic solution under occlusive dressing. A double blind comparative study. Dermatologica 1972;145(6):395-9.
47. Negro-Vilar A, Dziewanowska Z, Groves ES, Stevens V, Zhang JK, Prince M, et al.Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL) [Abstract 8026]. ASCO annual meeting proceedings. Journal of Clinical Oncology 2007;25(18S Suppl June):447.
48. No authors listed. Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma. Cancer Treatment Reports 1982;66(1):49-55.
49. Olsen EA, Diab NG. Interferon alfa-2A in the treatment of cutaneous T cell lymphoma [Abstract]. 47th Annual Meeting of The Society for Investigative Dermatology, Inc, Washington, D.C. 1-4 May 1986. Journal of Investigative Dermatology 86;4:498. [DOI: 10.1111/1523-1747.ep12285810].
50. Pan Y, Prince HM, Ellis L, Culver K. LBH589, a Novel Deacetylase Inhibitor (DACi), in the Treatment of Cutaneous T-Cell Lymphoma (CTCL): Changes in tumor Gene Expression Profiles Related to Clinical Response after Therapy. [Abstract 00172]. The 11th World Congress on Cancers of the Skin. Amsterdam, The Netherlands. 8th-11th June 2007. 2007.
51. Peugeot RL. Clinical efficacy of a novel purine nucleoside phosphorylase inhibitor (BCX-34) in the treatment of cutaneous T-cell lymphoma. [Abstract 54]. 1995 Annual Meeting of the Society for Investigative Dermatology. Journal of Investigative Dermatology 1995;104(4):563.
52. Plettenberg H, Stege H, Megahed T, Ruzicka T, Hosokawa Y, Tsuji T, et al.UVA1-Phototherapie versus PUVA-Photochemotherapie in der Behandlung von Patienten mit kutanem T-Zell-Lymphom (CTCL). Zeitschrift für Hautkrankheiten 2001;76(Suppl 1):S96.
53. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, et al.Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology 2010;28(11):1870-7. [PUBMED: 20212249].
54. Schrag H-J, Dippel E, Goerdt S, Orfanos C E. Extracorporal photophoresis (ECP) + Interferon-alpha 2a vs. ECP in patients with cutaneous T-cell lymphoma. Evaluation using a new score (CTCL-SI) (German). Der Hautarzt 1997;48(Suppl):S96.
55. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al.Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. British Journal of Haematology 2010;151(2):159-66. [PUBMED: 20738307].
56. Thomsen K. Scandinavian mycosis fungoides study group. Bulletin du Cancer 1977;64(2):287-90. [PUBMED: 912132].
57. Wain EM, Whittaker SJ, Russell-Jones R. A randomized, open, crossover study to compare the efficacy of extracorporeal photopheresis with methotrexate in the treatment of erythrodermic primary cutaneous T-cell lymphoma. [Abstract RF-5]. The 85th BAD Annual Meeting 5-8th July 2005, Glasgow, UK. British Journal of Dermatology 2005;153(Suppl 1):10.
58. Wiernik PH, Moore DF, Bennett JM, Vogl SE, Harris JE, Luger S, et al.Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481). Leukemia & Lymphoma 1998;30(5-6):601-7.
59. Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GL, Shnider B, et al.Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. Journal of Chronic Diseases 1960;11(1):7-33.
60. Foss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. American Journal of Hematology 2011;86(7):627-30.
61. Lessin S, Duvic M, Guitart J, Pandya A, Strober B, Olsen E, et al.Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf) [Abstract 503]. Annual Meeting of the Society for Investigative Dermatology Phoenix, AZ United States, 4-7 May 2011. Journal of Investigative Dermatology 2011;131(Suppl 1):S84.
62. NCT00056056. Phase III Randomized Study of Ultraviolet A Light Therapy With Methoxsalen (PUVA) With or Without Bexarotene in Patients With Mycosis Fungoides. clinicaltrials.gov/ct/show/NCT00056056 (accessed 24 September 2011).
63. NCT00091208. A Phase I/II Open Label, Multi-Center Study For The Evaluation Of CPG 7909 In Patients With Stage IB To IVA Cutaneous T-Cell Lymphoma. clinicaltrials.gov/ct/show/NCT00091208 (accessed 15 September 2011).
64. NCT00168064. A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF). clinicaltrials.gov/ct/show/NCT000168064 (accessed 3 October 2011).
65. NCT01007448. Phase IV Randomized Study Of Two Dose Levels Of Targretin Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma. clinicaltrials.gov/ct/show/NCT01007448 (accessed 15 September 2011).
66. NCT01098656. A Phase III Study of Lenalidomide Maintenance After Debulking With Gemcitabine or Liposomal Doxorubicin +/- Radiotherapy in Patients With Advanced Cutaneous T-Cell Lymphoma Not Previously Treated With Intravenous Chemotherapy. clinicaltrials.gov/ct/show/NCT01098656 (accessed 15 September 2011).
67. NCT01187446. A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF). clinicaltrials.gov/ct/show/NCT01187446 (accessed 15 September 2011).
68. NCT01386398. Vorinostat (Zolinza®) in Combination With (Velcade®) Versus Vorinostat Alone in Refractory or Recurrent Advanced CTCL: A Randomized Phase III Study. clinicaltrials.gov/ct/show/NCT01386398 (accessed 15 September 2011).
69. NCT01433731. A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assessthe Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone DeacetylaseInhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA CutaneousT-Cell Lymphoma. clinicaltrials.gov/ct/show/NCT01433731 (accessed 29 April 2012).
70. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al.Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Journal of Clinical Oncology 2010;28(31):4730-9. [PUBMED: 20855822].
71. Bernstein L, Deapen D, Ross RK. Mycosis fungoides. JAMA 1989;261(13):1882. [PUBMED: 2784510].
72. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113(21):5064-73. [PUBMED: 19279331].
73. Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treatment Reports 1979;63(4):725-8. [PUBMED: 445521].
74. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al.The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993;11(3):570-9. [PUBMED: 8445433].
75. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457-65.
76. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of Dermatology 2007;143(7):854-9. [PUBMED: 17638728].
77. Dekkers OM, von Elm E, Algra A, Romijn JA, Vandenbroucke JP. How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology 2010;39(1):89-94. [PUBMED: 19376882].
78. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-91. [PUBMED: 7718048].
79. Dummer R, Dreyling M. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2008;19(Suppl 2):ii72-6. [PUBMED: 18456777].
80. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clinical Medicine 2001;1(6):478-84. [PUBMED: 11792089].
81. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Current Opinion in Oncology 2009;21(2):131-7. [PUBMED: 19532014].
82. Grant B. Biotech Baddies. The Scientist 2009;23(4):48. [http://classic.the-scientist.com/article/display/55525/].
83. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983;249(13):1743-5. [PUBMED: 6827763].
84. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
85. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [PUBMED: 10480822].
86. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet 2008;371(9616):945-57. [PUBMED: 18342689].
87. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and Genetics: Tumours of Hematopoetic and Lymphoid Tissues (World Health Organization Classification of Tumours). Lyon: IARC Press, 2001.
88. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6. [PUBMED: 11440947].
89. Jüni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: Empirical study. International Journal of Epidemiology 2002;31(1):115-23. [PUBMED: 11914306].
90. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Archives of Dermatology 1996;132(11):1309-13. [PUBMED: 8915308].
91. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Archives of Dermatology 2003;139(7):857-66. [PUBMED: 12873880].
92. Lorincz AL. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 1996;347(9005):871-6. [PUBMED: 8622396].
93. Miettinen O, Nurminen M. Comparative analysis of two rates. Statistics in medicine 1985;4(2):213-26. [PUBMED: 4023479].
94. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Controlled Clinical Trials 1995;16(1):62-73. [PUBMED: 7743790].
95. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12. [PUBMED: 19631508].
96. Molin L, Thomsen K, Volden G. Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group. Acta Dermato-Venereologica 1979;59(1):64-8. [PUBMED: 84470].
97. Morales Suárez-Varela MM, Llopis González A, Marquina Vila A, Bell J. Mycosis fungoides: Review of epidemiological observations. Dermatology 2000;201(1):21-8. [PUBMED: 10971054].
98. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al.Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110(6):1713-22. [PUBMED: 17540844].
99. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al.Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology 2011;29(18):2598-607. [PUBMED: 21576639].
100. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, et al.Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Annals of Internal Medicine 1988;109(5):372-82. [PUBMED: 3408055].
101. Scheffer E, Meijer CJ, Van Vloten WA. Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides. Cancer 1980;45(1):137-48. [PUBMED: 7350998].
102. Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD008908.pub2].
103. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. Journal of Chronic Diseases 1981;34(12):585-97. [PUBMED: 7309824].
104. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al.EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. European Journal of Cancer 2006;42(8):1014-30. [PUBMED: 16574401].
105. van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, et al.Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Archives of Dermatology 2000;136(4):504-10. [PUBMED: 10768649].
106. Van Scott EJ, Kalmanson JD. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer 1973;32(1):18-30. [PUBMED: 4577503].
107. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al.The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. Journal of Clinical Epidemiology 1998;51(12):1235-41. [PUBMED: 10086815].
108. Vonderheid EC, Pena J, Nowell P. Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and staging. Leukemia & Lymphoma 2006;47(9):1841-56. [PUBMED: 17064997].
109. Wain EM, Orchard GE, Whittaker SJ, Spittle MF, Russell-Jones R. Outcome in 34 patients with juvenile-onset mycosis fungoides: A clinical, immunophenotypic, and molecular study. Cancer 2003;98(10):2282-90. [PUBMED: 14601100].
110. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988;260(1):42-6. [PUBMED: 3379722].
111. Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States. Cancer 1999;85(1):208-12. [PUBMED: 9921994].
112. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. British Journal of Dermatology 2003;149(6):1095-1107. [PUBMED: 14696593].
113. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al.EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90(1):354-71. [PUBMED: 9207472].
114. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al.WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105(10):3768-85. [PUBMED: 15692063].
115. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood & Marrow Transplantation 2009;15(8):982-90.
116. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. Journal of the American Academy of Dermatology 1999;40(3):418-25. [PUBMED: 10071312].